» Articles » PMID: 37547619

Prevalence and Risk Factors of Toxigenic Asymptomatic Carriage in 11 French Hospitals

Abstract

infection (CDI) incidence has increased over the last 20 years. Studies suggest that asymptomatic carriers may be an important reservoir of in healthcare settings. We conducted a point prevalence study to estimate the toxigenic asymptomatic carriage rate and the associated risk factors in patients >3 years old. Between September 16, 2019 and January 15, 2020, all patients hospitalized in 11 healthcare facilities in the Paris urban area were included in the study. They were screened on the day of the survey for toxigenic carriage by rectal swab and interviewed. Isolates were characterized by PCR ribotyping and multiplex PCR targeting toxin genes. A logistic regression model was used to determine the risk factors associated with toxigenic asymptomatic carriage using uni- and multivariate analysis in the subpopulation of patients >3 years old. During the study period, 2,389 patients were included and screened. The median age was 62 years (interquartile range 35-78 years) and 1,153 were male (48.3%). Nineteen patients had a previous CDI (0.9%). Overall, 185/2389 patients were positive for (7.7%), including 93 toxigenic strains (3.9%): 77 (82.8%) were asymptomatic (prevalence 3.2%) whereas 12 (12.9%) were diarrheic. Prevalences of toxigenic were 3.5% in patients >3 years old and 7.0% in ≤3 years old subjects, respectively. Toxigenic strains mainly belonged to PCR ribotypes 106 ( = 14, 15.0%), 014 ( = 12, 12.9%), and 020 ( = 10, 10.8%). Among toxigenic strains, 6 (6.4%) produced the binary toxin. In multivariate analysis, two factors were positively associated with toxigenic asymptomatic carriage in patients >3 years old: multidrug-resistant organisms co-carriage [adjusted Odd Ratio (aOR) 2.3, CI 95% 1.2-4.7,  = 0.02] and previous CDI (aOR 5.8, CI 95% 1.2-28.6,  = 0.03). Conversely, consumption of raw milk products were associated with reduced risk of toxigenic colonization (aOR 0.5, CI 95% 0.2-0.9,  = 0.01). We showed that there was a low prevalence of asymptomatic toxigenic carriage in hospitalized patients. Consumption of raw milk prevents toxigenic colonization, probably due to the barrier effect of milk-associated bacteria.

Citing Articles

Heterogeneity of Clostridioides difficile asymptomatic colonization prevalence: a systematic review and meta-analysis.

De-la-Rosa-Martinez D, Villasenor-Echavarri R, Vilar-Compte D, Mosqueda-Larrauri V, Zinser-Peniche P, Blumberg S Gut Pathog. 2025; 17(1):6.

PMID: 39871276 PMC: 11773978. DOI: 10.1186/s13099-024-00674-0.


Short-sighted evolution of virulence for invasive gut microbes: From hypothesis to tests.

Scanlan P, Baquero F, Levin B Proc Natl Acad Sci U S A. 2024; 121(49):e2409905121.

PMID: 39570365 PMC: 11626195. DOI: 10.1073/pnas.2409905121.


Mortality Attributable to Infection: The Rising Burden of Disease in European Countries.

Ilic I, Zivanovic Macuzic I, Ilic M Medicina (Kaunas). 2024; 60(8).

PMID: 39202503 PMC: 11355982. DOI: 10.3390/medicina60081222.


Can the Evidence-Based Use of Probiotics (Notably Saccharomyces boulardii CNCM I-745 and Lactobacillus rhamnosus GG) Mitigate the Clinical Effects of Antibiotic-Associated Dysbiosis?.

Waitzberg D, Guarner F, Hojsak I, Ianiro G, Polk D, Sokol H Adv Ther. 2024; 41(3):901-914.

PMID: 38286962 PMC: 10879266. DOI: 10.1007/s12325-024-02783-3.

References
1.
Jangi S, Lamont J . Asymptomatic colonization by Clostridium difficile in infants: implications for disease in later life. J Pediatr Gastroenterol Nutr. 2010; 51(1):2-7. DOI: 10.1097/MPG.0b013e3181d29767. View

2.
Davies K, Ashwin H, Longshaw C, Burns D, Davis G, Wilcox M . Diversity of Clostridium difficile PCR ribotypes in Europe: results from the European, multicentre, prospective, biannual, point-prevalence study of Clostridium difficile infection in hospitalised patients with diarrhoea (EUCLID), 2012 and 2013. Euro Surveill. 2016; 21(29). DOI: 10.2807/1560-7917.ES.2016.21.29.30294. View

3.
Kuijper E, Coignard B, Tull P . Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006; 12 Suppl 6:2-18. DOI: 10.1111/j.1469-0691.2006.01580.x. View

4.
Le Monnier A, Duburcq A, Zahar J, Corvec S, Guillard T, Cattoir V . Hospital cost of Clostridium difficile infection including the contribution of recurrences in French acute-care hospitals. J Hosp Infect. 2015; 91(2):117-22. DOI: 10.1016/j.jhin.2015.06.017. View

5.
Eckert C, Coignard B, Hebert M, Tarnaud C, Tessier C, Lemire A . Clinical and microbiological features of Clostridium difficile infections in France: the ICD-RAISIN 2009 national survey. Med Mal Infect. 2013; 43(2):67-74. DOI: 10.1016/j.medmal.2013.01.004. View